Befejeződött1/2. fázis
A study to investigate safety and efficacy with SAR445514 in participants with relapsed/refractory multiple myeloma (RRMM) and relapsed/refractory light-chain amyloidosis (RRLCA)
Key facts
- Where
- Budapest IX és Budapest VIII, MagyarországSee the 2 sites
- Phase
- 1/2. fázis
Where in Magyarország
- Del-Pesti Centrumkorhaz Orszagos Hematologiai Es Infektologiai IntezetBudapest IX, MagyarországNo longer taking part
- Semmelweis UniversityBudapest VIII, MagyarországNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Sanofi-Aventis Recherche & Developpement
- Trial code
- EU 2022-502057-33-00
- Record updated
- 2025. május 21.